B. Ahrén, Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives, Diabetes & Metabolism, vol.39, issue.3, 2013.
DOI : 10.1016/j.diabet.2013.03.001

A. Avignon and J. Sauvanet, Liraglutide pour le traitement du diab??te de type 2, M??decine des Maladies M??taboliques, vol.4, issue.3, p.31325, 2010.
DOI : 10.1016/S1957-2557(10)70066-3

L. Baggio and D. Drucker, Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, p.213157, 2007.
DOI : 10.1053/j.gastro.2007.03.054

J. Beaudeux and D. G. , Biochimie médicale, marqueurs actuels et perspectives, 2011.

J. Beaudeux and D. G. , Biochimie médicale. Marqueurs actuels et perspectives, 2011.

N. Belin and F. Bontemps, Le diabète de type 2. Le Moniteur Formation, 2014.

D. Block, C. , V. Gaal, and L. , GLP-1 receptor agonists for type 2 diabetes. The Lancet. 10 juill, p.46, 2009.

B. Bode, An overview of the pharmacokinetics, efficacy and safety of liraglutide, Diabetes Research and Clinical Practice, vol.97, issue.1, p.2742, 2012.
DOI : 10.1016/j.diabres.2011.12.015

F. Bontemps and C. Fusi, Le diabète de type 1. Le Moniteur Formation. 11 janv 2014, p.3014

H. Bourezane, B. Kastler, and J. Kantelip, Acute necrotizing pancreatitis with liraglutide, THERAPIE. Ther J Société Fr Pharmacol Thérapeutique. nov, vol.67, issue.6, p.491554, 2012.

J. Buse, M. Nauck, T. Forst, W. Sheu, S. Shenouda et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. The Lancet. The Lancet. 12 janv 2013, p.89176

M. Buysschaert, Diabétologie clinique. 4e édition, 2011.

D. Cohen, Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, BMJ. BMJ. 27 avr, vol.346, issue.7905, 2013.

D. Cohen, Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows, BMJ, vol.346, issue.feb27 2, 2013.
DOI : 10.1136/bmj.f1304

. Collège-de-la-haute-autorité-de-santé, Stratégie médicamenteuse du contrôle glycémique du diabète de type 2 Recommandations HAS/ANSM janvier 2013

L. Craz, S. Bontemps, and F. , Les analyses biologiques. Le moniteur formation. 12 avr 2014

M. Dailey and T. Moran, Glucagon-like peptide 1 and appetite, Trends in Endocrinology & Metabolism, vol.24, issue.2, p.8591, 2013.
DOI : 10.1016/j.tem.2012.11.008

G. Fischer-ghanassia-patricia and . Grego, Endocrinologie Nutrition [Internet]. 6e édition Disponible sur: http://www.unitheque.com/Livre, VERNAZOBRES, 2011.

J. Gautier, S. Choukem, and J. Girard, Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes, Diabetes & Metabolism, vol.34, issue.2, p.6572, 2008.
DOI : 10.1016/S1262-3636(08)73397-4

F. Giorgino, L. Laviola, A. Leonardini, and A. Natalicchio, GLP-1: a new approach for type 2 diabetes therapy, Diabetes Research and Clinical Practice, vol.74, issue.2, p.1525, 2006.
DOI : 10.1016/S0168-8227(06)70021-3

A. Grimaldi, Diab??te, pp.37-38452, 2013.
DOI : 10.1016/B978-2-294-01781-0.50147-3

J. Gutzwiller, L. Degen, L. Heuss, and C. Beglinger, Glucagon-like peptide 1 (GLP-1) and eating, Physiology & Behavior, vol.82, issue.1, p.179, 2004.
DOI : 10.1016/j.physbeh.2004.04.019

A. Hattersley, Prime suspect: the TCF7L2 gene and type 2 diabetes risk, Journal of Clinical Investigation, vol.117, issue.8, p.20779, 2007.
DOI : 10.1172/JCI33077

K. Kazakos, Incretin effect: GLP-1, GIP, DPP4, Diabetes Research and Clinical Practice, vol.93, p.326, 2011.
DOI : 10.1016/S0168-8227(11)70011-0

M. Lind, Incretin therapy and its effect on body weight in patients with diabetes, Primary Care Diabetes, vol.6, issue.3, p.18791, 2012.
DOI : 10.1016/j.pcd.2012.04.006

M. Lind, J. Jendle, O. Torffvit, and I. Lager, Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction, Primary Care Diabetes, vol.6, issue.1, p.416, 2012.
DOI : 10.1016/j.pcd.2011.09.002

R. Lloyd, B. Douglas, and W. Young, Endocrine Diseases Atlas of nontumor pathology. First series. Fascicle 1. American Registry of Pathology (APR) and the Armed Forces Institute of Pathology (AFIP), 2002.

J. Lubetzi, P. Chanson, and P. Guillausseau, Endocrinologie et maladies métaboliques. 3e édition. Flammarion-Médecine Sciences, 2005.

J. Luton, P. Thomopoulos, A. Basdevant, and . Endocrinologie, Nutrition et maladies métaboliques. Flammarion-Médecine Sciences, 1999.

V. Lyssenko, R. Lupi, P. Marchetti, D. Guerra, S. Orho-melander et al., Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes, Journal of Clinical Investigation, vol.117, issue.8, p.215563, 2007.
DOI : 10.1172/JCI30706DS1

L. Mandereau-bruno, P. Denis, A. Fagot-campagna, and S. Fosse-edorh, Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en 2012, Disponible sur, pp.30-31493, 2014.

M. Marre and A. Penfornis, GLP-1 receptor agonists today, Diabetes Research and Clinical Practice, vol.93, issue.3, p.31727, 2011.
DOI : 10.1016/j.diabres.2011.01.004

R. Nakanishi, T. Hirose, Y. Tamura, Y. Fujitani, and H. Watada, Attempted suicide with liraglutide overdose did not induce hypoglycemia. Brief report, 2012.

M. Nauck, F. Stöckmann, R. Ebert, and W. Creutzfeldt, Reduced incretin effect in Type 2 (noninsulin-dependent ) diabetes, Diabetologia. 1 janv, vol.29, issue.1, p.4652, 1986.

F. Netter, Atlas d'anatomie humaine, Masson et Icon Learning Systems, 2004.

C. Suen and P. Burn, The potential of incretin-based therapies in type 1 diabetes, Drug Discovery Today, vol.17, issue.1-2, p.8995, 2012.
DOI : 10.1016/j.drudis.2011.08.017

J. Tourniaire, Endocrinologie Diabète Nutrition pour le praticien. SIMEP, 1994.

D. Yabe and Y. Seino, Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and ?? cell preservation, Progress in Biophysics and Molecular Biology, vol.107, issue.2, p.24856, 2011.
DOI : 10.1016/j.pbiomolbio.2011.07.010